Abstract
Nitric oxide (NO) is known to have dichotomous effects on cancer biology, acting as a pro- or antineoplastic agent. Low concentrations of NO are reported to promote tumor growth, whereas high NO influx acts as a potent tumor repressor, leading to cytotoxicity and apoptosis. There is increasing interest in developing NO-releasing materials as potent tumoricidal agents in which high and localized concentrations of NO may be directly released in a sustained manner to the tumor site. Nanomaterials allied to NO donors have emerged as a promising strategy in cancer treatment. In this context, this review summarizes the roles of NO in cancer biology and highlights the therapeutic potential effects of NO-releasing nanomaterials based on polymeric nanoparticles, dendritic polymers, liposomes, silica nanoparticles, metallic nanoparticles and quantum dots in combating tumor cells.
Keywords: Cancer, Cytotoxicity, Dendrimers, Diazeniumdiolates, Liposomes, Metallic nanoparticles, Nanomaterials, Nitric Oxide, Polymeric nanoparticles, Quantum dots, Silica nanoparticles, S-nitrosothiols.
Current Topics in Medicinal Chemistry
Title:Nitric Oxide Releasing Nanomaterials for Cancer Treatment: Current Status and Perspectives
Volume: 15 Issue: 4
Author(s): Amedea B. Seabra, Renata de Lima and Marcelo Calderón
Affiliation:
Keywords: Cancer, Cytotoxicity, Dendrimers, Diazeniumdiolates, Liposomes, Metallic nanoparticles, Nanomaterials, Nitric Oxide, Polymeric nanoparticles, Quantum dots, Silica nanoparticles, S-nitrosothiols.
Abstract: Nitric oxide (NO) is known to have dichotomous effects on cancer biology, acting as a pro- or antineoplastic agent. Low concentrations of NO are reported to promote tumor growth, whereas high NO influx acts as a potent tumor repressor, leading to cytotoxicity and apoptosis. There is increasing interest in developing NO-releasing materials as potent tumoricidal agents in which high and localized concentrations of NO may be directly released in a sustained manner to the tumor site. Nanomaterials allied to NO donors have emerged as a promising strategy in cancer treatment. In this context, this review summarizes the roles of NO in cancer biology and highlights the therapeutic potential effects of NO-releasing nanomaterials based on polymeric nanoparticles, dendritic polymers, liposomes, silica nanoparticles, metallic nanoparticles and quantum dots in combating tumor cells.
Export Options
About this article
Cite this article as:
Seabra B. Amedea, de Lima Renata and Calderón Marcelo, Nitric Oxide Releasing Nanomaterials for Cancer Treatment: Current Status and Perspectives, Current Topics in Medicinal Chemistry 2015; 15 (4) . https://dx.doi.org/10.2174/1568026615666150108122918
DOI https://dx.doi.org/10.2174/1568026615666150108122918 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Detection of Tumor Markers with ProteinChip® Technology
Current Pharmaceutical Biotechnology Synthetic 2-Methoxyestradiol Derivatives: Structure-Activity Relationships
Current Medicinal Chemistry Cerebral Aneurysm as an Exacerbating Factor in Stroke Pathology and a Therapeutic Target for Neuroprotection
Current Pharmaceutical Design Structure, Biological Properties and Applications of Marine-derived Polysaccharides
Current Organic Chemistry Editorial (Thematic Issue: Chemoresistance in Gynecologic Cancers)
Current Cancer Therapy Reviews Radiation-Induced Extracranial Carotid Stenosis
Vascular Disease Prevention (Discontinued) Phytosynthesized Nanoparticles for Effective Cancer Treatment: A Review
Nanoscience & Nanotechnology-Asia Exploring Optic Nerve Axon Regeneration
Current Neuropharmacology Current Developments of Coumarin Compounds in Medicinal Chemistry
Current Pharmaceutical Design The Immunological Side-Effects of Sedative Agents in the Intensive Care Unit
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Role of Chromogranin A (CgA) in Monitoring Patients with Prostate Cancer Under Androgen Deprivation Therapy: Comparison with Prostatic Specific Antigen (PSA)
Current Radiopharmaceuticals Compartmentalized Platforms for Neuro-Pharmacological Research
Current Neuropharmacology Novel Analogues of CC-1065 and the Duocarmycins for the Use in Targeted Tumour Therapies
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs and Cancer; an Overview
Current Pharmaceutical Biotechnology Inhibition of Disulfide Reductases as a Therapeutic Strategy
Current Enzyme Inhibition Targeting Autophagic Pathways by Plant Natural Compounds in Cancer Treatment
Current Drug Targets Anticarcinogenic Actions of Tributyrin, A Butyric Acid Prodrug
Current Drug Targets The GABAergic System and the Gastrointestinal Physiopathology
Current Pharmaceutical Design Synthesis, Characterization by Means of IR, 1H, 13C - NMR and Biological Investigations on New Diorganotin Carboxylic Acid Derivatives
Letters in Drug Design & Discovery Recent Developments in the Formulation of Nanoliposomal Delivery Systems
Current Nanomaterials